Novel technologies: A weapon against tuberculosis

Indian Journal of Pharmacology

Volumn 42, Issue 6, 2010, Pages 338-344

  Vedha Hari, B N ^a   Priya Chitra, Karuna ^a   Bhimavarapu, Ramadevi ^a   Karunakaran, Prabhu ^b   Muthukrishnan, N ^a   Samyuktha Rani, B ^a  

^a SASTRA UNIVERSITY   (India)

^b SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Nanotechnology; polymers; targeted site; tuberculosis

Indexed keywords

ABRIFAM; AETINA; AMIKACIN; AMINOSALICYLIC ACID; ARGININE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ENVIOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LIPOSOME; MICROSPHERE; MOXIFLOXACIN; NANOPARTICLE; NIOSOME; POLYMER; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPRODIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIOMYCIN; VITAMIN D;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MICELLE; MICROENCAPSULATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; PATIENT COMPLIANCE; REVIEW; TREATMENT FAILURE; TUBERCULOSIS;

EID: 78149401710     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.71887     Document Type: Review

References (42)

1. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis. Nat Med 2005;11:33-44.
2. Gaspar MM, Cruz A, Fraga, Castro AG, Cruz MEM, Pedrosa J. Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections. Curr Top Med Chem 2008;8:579-91.
3. Tuberculosis. The International Union against Tuberculosis and Lung Disease (The Union).
4. Du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: Current drug delivery approaches. Resp Res 2006;7:1-18.
5. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microb Rev 2003;16:463-96.
6. Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes M, et al. Treatment of tuberculosis: Present status and future prospects. Bull. World Health Organ 2005;83:857-65.
7. Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938-40.
8. Springhouse. Professional guide to disease. Lippincott and Williams and Wilkims publisher; New Yark 2005. P. 200-25.
9. Available from: http://www.health.state.mn.us/divs/idepc/diseases/tb/ phaseschart.html. [cited in 2010].
10. Iseman MD. Treatment of multidrug - resistant tuberculosis. N Engl J Med 1993;329:784-91.
11. Center for Disease Control. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drug-Worldwide, 2000-2004. MMWR Wkly 2006;55:301-05.
12. Grange JM, Zumla A. The global emergency of tuberculosis: What is the cause? The Journal of the Royal Society for the Promotion of Health 2002;122:78-81.
13. Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis 2008;88:3-17.
14. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Muller R H, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000;45:77-83.
15. Constantinides PP, Chaubal MV, Shorr R. Advances in lipidnanodispersions for parenteral drug delivery and targeting. Adv Drug Del Rev 2008;60:757-67.
16. Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm 2004;273:75-83.
17. Varaporn Buraphacheep Junyaprasert, Veerawat Teeranachaideekul, Tasaneeya Supaperm. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS Pharm Sci Tech 2008;9:851-9.
18. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JFB, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985;37:237-42.
19. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20.
20. Delie F, Blanco-Prieto MJ, Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 2005;10:65-80.
21. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm 1995;116:1-9.
22. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2005;307:93-102.
23. Du Toit LC, Pillay V, Choonara YE, Iyuke SE. Formulation and evaluation of a salted-out isoniazid-loaded nanosystem. AAPS Pharm SciTech 2008;9:174-81.
24. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Deliv Rev 2001;47:113-31.
25. Croy SR, Kwon GS. Polymeric Micelles for drug delivery. Curr Pharm Design 2006;12:4669-84.
26. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonisation but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1993;1179:157-65.
27. Chen L, Xie Z, Hu J, Chen X, Jing X. Enantiomeric PLA-PEG block copolymers and their stereocomplex micelles used as rifampin delivery. J Nanoparticle Res 2007;9:777-85.
28. Emanuele AD, Attwood D. Dendrimer-drug interactions. Adv Drug Del Rev 2005;57:2147-62.
29. Duncan R, Izzo L. Dendrimers biocompatibility and toxicity. Adv Drug Del Rev 2005;57:2215-37.
30. Kumar PV, Agashe H, Dutta T, Jain NK. PEgylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Current Drug Delivery 2007;4:11-9.
31. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329:1-11.
32. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007;59:645-66.
33. Rao KR, Yadav N, Singh J, Krishnaveni. Inclusion complex of anti-tubercular rifampicin with beta-cyclodextrin or 2-hydroxypropyl beta-cyclodextrin and a process for producing the same. European Patent EP1581226.
34. Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy. Lancet 1974;1:1313-16.
35. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004;269:457-67.
36. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung- specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicro Agents Chemother 1997;41:1211-14.
37. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Del Rev 2008;60:863-75.
38. Muttil P, Wang C, Hickey AJ. Inhaled Drug Delivery for Tuberculosis Therapy. Pharmaceutical research 2009. p. 2401-16.
39. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GI. Biodegradation of and tissue reaction to microcapsules. J Biomed Mater Res 1986;20:667-76.
40. Tice TR, Cowsar DR. Biodegradable controlled-release parenteral systems. J Pharm Technol 1984;8:26-35.
41. Wu Y, Li M, Gao H. Polymeric micelle composed of PLA and chitosan as a drug carrier. J Polym Res 2009;16:11-8.
42. Comstock GW. The age of selection of mortality from tuberculosis in successive decades. Am J Epidemiol; 1995. P. 141-790.